Cannabis-based medicines can be prescribed on the NHS, but only for a narrow group of patients. The NHS itself says very few people in England are likely to receive one. This guide explains which medicines are used, for which conditions, and how the rules differ across the UK. It is general information, not legal or medical advice.
Key points
- Three cannabis-based medicines are used on the NHS: Epidyolex, Sativex and nabilone.
- The main conditions are certain rare severe epilepsies, multiple sclerosis (MS) spasticity, and sickness caused by chemotherapy.
- NICE does not recommend cannabis-based medicines for chronic pain, except within clinical trials.
- Unlicensed cannabis medicines must be started by a hospital specialist, and GPs cannot refer you simply because you ask.
- Scotland and Northern Ireland follow broadly similar approaches, with their own decision-making bodies.
The medicines used on the NHS
Epidyolex (cannabidiol)
Epidyolex is a highly purified CBD oral solution, licensed in the UK. It does not contain THC. NICE recommends it, alongside the epilepsy medicine clobazam, for seizures linked to Lennox-Gastaut syndrome (TA615) and Dravet syndrome (TA614) in people aged 2 and over, where certain conditions are met.
In 2023 NICE also recommended it as an add-on treatment for seizures caused by tuberous sclerosis complex (TA873) in people aged 2 and over whose seizures are not controlled by two or more other medicines. Seizure frequency is checked every six months, and treatment is stopped if it has not fallen by at least 30%.
Sativex (nabiximols)
Sativex is a mouth spray containing THC and CBD. It is licensed for adults with moderate to severe spasticity caused by MS that has not improved enough with other treatments. NICE guideline NG144 recommends a four-week trial, started and supervised by a doctor with expertise in MS spasticity, with treatment continuing only if symptoms improve by at least 20%.
Nabilone
Nabilone is a capsule containing a man-made cannabinoid that acts in a similar way to THC. NICE says it can be considered as an add-on treatment for adults whose nausea and vomiting from chemotherapy continues despite standard anti-sickness medicines.
What NICE says about other uses
NICE published its guideline on cannabis-based medicinal products (NG144) in November 2019. Its main conclusions are:
- Chronic pain: NICE recommends against nabilone, THC, combined THC and CBD products, and CBD alone for chronic pain, except as part of a clinical trial. People who were already receiving treatment before the guideline can continue until they and their NHS clinician agree it is appropriate to stop.
- Severe treatment-resistant epilepsy: apart from Epidyolex for the conditions above, NICE found the evidence too limited to make a recommendation and called for more research.
- Prescribing: the first prescription for a cannabis-based medicine (other than nabilone) should come from a specialist doctor with an interest in the condition. Later prescriptions can be issued by another prescriber, such as a GP, under shared care.
Who can get an NHS prescription
In practice you would need to be under the care of a hospital specialist for one of the conditions above, and to have tried other treatments first. The NHS advises that if you do not meet the criteria, there is no point asking your GP for a referral to discuss medical cannabis.
Unlicensed cannabis products, such as oils or flower containing THC, are very rarely prescribed on the NHS. The Care Quality Commission does not publish NHS prescribing figures because the numbers are so small that patients could be identified. Most people receiving unlicensed products are treated privately, which our separate prescription guide explains.
Scotland
In Scotland the Scottish Medicines Consortium (SMC) decides whether new medicines are accepted for use in NHSScotland. It accepted Epidyolex for Lennox-Gastaut and Dravet syndromes in September 2020, and for tuberous sclerosis complex in 2022. It accepted Sativex for MS spasticity in September 2022, under similar conditions to NICE. Unlicensed products are prescribed only rarely, on an individual patient basis.
Northern Ireland
The Department of Health in Northern Ireland allowed specialist prescribing of cannabis-based medicines from 1 November 2018, on the same basis as Great Britain. It confirms these medicines are not available from GPs. It also runs a specialist clinical advisory service (RESCAS) for clinicians considering cannabis-based medicines for refractory epilepsy.
Is anything changing?
The ACMD is reviewing the effect of the 2018 law change, including whether private prescribing has reduced the incentive to run the clinical trials needed for wider NHS use. NICE guidance is reviewed when significant new evidence emerges. As of October 2026 the NHS position described here had not changed.
Frequently asked questions
Can I get medical cannabis on the NHS for chronic pain?
Generally no. NICE recommends against cannabis-based medicines for chronic pain outside clinical trials, because the evidence of benefit was not strong enough. People who were already being treated on the NHS before the guideline came out may continue.
Is Epidyolex the same as CBD oil from a shop?
No. Epidyolex is a licensed medicine made to pharmaceutical standards and prescribed by specialists for specific epilepsies. Shop-bought CBD products are sold as foods, contain much less CBD and are not assessed as medicines.
Can my GP refer me for medical cannabis?
A GP can refer you to a specialist for your condition, but only a specialist can decide whether a cannabis-based medicine is appropriate. The NHS advises that if you do not meet the criteria for the conditions it covers, a referral to discuss medical cannabis is unlikely to help.
Is Sativex available in Scotland?
Yes. The Scottish Medicines Consortium accepted Sativex in September 2022 for adults with moderate to severe MS spasticity who have not responded well enough to other treatments and who improve during an initial trial.
Sources
- Medical cannabis (and cannabis oils) (NHS)
- NICE guideline NG144: Cannabis-based medicinal products
- NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
- NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox-Gastaut syndrome
- NICE TA873: Cannabidiol for treating seizures caused by tuberous sclerosis complex
- The safer management of controlled drugs: key issues in 2024 (Care Quality Commission)
- SMC September 2020 decisions news release
- Cannabidiol (Epidyolex) for tuberous sclerosis complex, SMC2402 (Scottish Medicines Consortium)
- Delta-9-tetrahydrocannabinol and cannabidiol (Sativex) SMC2473 (Scottish Medicines Consortium)
- Cannabis-based medicinal products (Department of Health Northern Ireland)
- ACMD 3-year work programme 2025 to 2028: commissioning letter